Healthy Volunteers
Conditions
Keywords
Ebola Vaccine
Brief summary
Background: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. A vaccine to prevent infection either before or after exposure was approved in 2020 but the durability of the vaccine response is unknown. Researchers wish to study the potential to increase the antibody response to the licensed Ebola vaccine. An improved response before exposure to the virus potentially could increase the vaccine's effectiveness in preventing disease. Objectives: To see if the antibody response to the vaccine, rVSV∆G-ZEBOV-GP vaccine (V920), could potentially be improved by providing a booster injection several months after the primary immunization. Eligibility: Healthy adults at risk of exposure to the Ebola virus at work through lab or clinical contact. Design: * Participants will be screened with medical history, physical exam, and blood tests. * Participants will get the study vaccine. It will be injected into their upper arm. * Participants will be monitored closely for at least 30 minutes. They will get a diary card to record any symptoms they have from the vaccine for up to 14 days. * Participants will have study visits at 1, 3, and 6 months after they get the vaccine, then every 6 months (that is, at months 12, 18, 19, 24, 30, and 36 of study) for a total of 36 months. * Eighteen months after they join the study, participants will be randomly assigned to one of two groups. One group will get a second (or booster) dose of the vaccine. The other group will not get a second dose. * This study lasts 36 months. In December 2024, the study was approved to re-enroll up to 30 participants from the primary cohort to check longer-term immune response to the study vaccine beyond 36 months.
Detailed description
Between 1994 and the present, there have been multiple Ebola virus outbreaks affecting mostly central Africa. However, the 2014/2015 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected, and in disruption of typical activities of civil society. This protocol is a multi-center study to evaluate the durability of the immune response following the open label administration of the rVSV∆G-ZEBOV-GP vaccine (V920) as pre-exposure prophylaxis for adults who have an occupational risk for potential exposure to Ebola virus. The vaccine uses a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (rVSV∆G-ZEBOV-GP vaccine also known as V920). All subjects will receive a single dose of rVSV∆G-ZEBOV-GP vaccine (V920) (\>=7.2 x 10\^7 pfu) on Day 0. We will collect adverse events after vaccination and at month 1 and month 19, serious adverse events (SAE) for the duration of the study, and assess the immune response at months 1, 3, 6, 12, 18, 19, 24, 30, and 36. A single booster immunization with the same dose of study vaccine as the primary dose (\>=7.2 x 10\^7 pfu/mL) will be given to those randomized at month 18 to the booster arm of the trial. However, if at any time during the observation period antibody levels fall below a predefined seroprotective threshold (yet to be defined in parallel or newly planned studies), a booster will be offered to those who have not previously received a booster injection.
Interventions
BIOLOGICALrVSV∆G-ZEBOV-GP Vaccine (V920)
Primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
Sponsors
National Institutes of Health Clinical Center (CC)
Emory University
Health Canada
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
-INCLUSION CRITERIA: 1. Adults age \>=18 years. 2. Signed informed consent for the trial. 3. At risk of occupational exposure to Ebola virus through laboratory, clinical contact, or field work, in the judgment of the investigator. 4. Females of childbearing potential must be willing to use effective methods of contraception, from at least 30 days prior to vaccination through 1 month following vaccination/booster, which would include: * oral contraceptives, either combined or progestogen alone * injectable progestogen * implants of etenogestrel or levonorgestrel * oestrogenic vaginal ring * percutaneous contraceptive patches * intrauterine device or intrauterine system * committed to abstinence from potentially reproductive sexual contact \[i.e. will NOT engage in heterosexual intercourse where both partners are capable of reproduction\] * surgical sterilization * male condom combined with a spermicide 5. All males must be willing to use effective methods of contraception for at least 1 month following vaccination/booster, which would include: * surgical sterilization * male condom combined with a spermicide 6. Willing to minimize blood and body fluid exposure to others for at least 14 days after vaccination/booster. This includes: * Use of effective barrier prophylaxis, such as latex condoms, during any sexual interaction (regardless of childbearing status or sexual orientation) * Avoiding the sharing of needles, razors, eating utensils, drinking from the same cup, or toothbrushes * Avoiding open-mouth kissing * Use of universal precautions in the health-care setting 7. Agrees not to receive another investigational agent between vaccination and the month 1 study visit (and booster and month 19 study visit). 8. Willing to forgo blood donation for one year from vaccination/booster. 9. Willing to accept randomization (boost versus no boost) at month 18 visit.
Exclusion criteria
1. Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk. Examples include: * Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health, per the investigator. A clinically significant condition or process includes but is not limited to: 1. A process that would adversely affect the systemic immune response 2. A process that would require medication that might adversely affect the systemic immune response 3. Any contraindication to repeated injections or blood draws 4. A condition that requires active medical intervention or monitoring to avert grave danger to the participant's health or well-being during the study period 5. A condition or process for which signs or symptoms could be confused with reactions to vaccine * Presence of any pre-existing illness or clinical history that, in the opinion of the investigator, would place the participant at an unreasonably increased risk through participation in this study. This includes but is not limited to: 1. Active malignancy 2. History of Guillain-Barre Syndrome 3. History of neurological disorder that may increase risk (history of encephalitis, stroke, or seizure) 4. Active autoimmune disorder requiring systemic immunosuppressive treatment * Any concomitant medication for which reported side effects or adverse events, in the judgment of the investigator, may interfere with assessment of safety. * Subjects who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol. 2. Pregnant or breast feeding (must have negative serum or urine pregnancy test on the day of vaccination, prior to vaccination) 3. Known allergy to the components of the rVSV∆G-ZEBOV-GP vaccine (V920) vaccine product (VSV, albumin, tris). 4. History of severe local or systemic reactions to any vaccination. 5. Received an investigational drug within 5 half-lives or 30 days, whichever is longer, prior to vaccination (Day 0)/booster (month 18). 6. Received killed vaccines 14 days before, or intention to receive within 7 days following, vaccination (Day 0)/booster (month 18). 7. Received live virus vaccines within 30 days before, or intention to receive live virus vaccines within 30 days following, vaccination (Day 0)/booster (month 18). 8. Received immunoglobulins and/or any blood products within the 120 days preceding vaccination (Day 0)/booster (month 18). 9. Received allergy treatment with antigen injections within 30 days before vaccination (Day 0)/booster (month 18). 10. Clinical evidence (e.g. oral temp \>38 degrees Celsius, systemic symptoms) of a systemic infection or other acute intercurrent illness at the proposed time of vaccination (Day 0)/booster (month 18).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Antibody Titres | Month 36 | The geometric mean antibody titres (GMT) was measured by Filovirus Animal Nonclinical Group ELISA at month 36 months for the randomized study cohort. |
Countries
Canada, United States
Contacts
PRINCIPAL_INVESTIGATORSusan L Moir, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
PRINCIPAL_INVESTIGATORNadine Rouphael, MD, MSc
The Hope Clinic of the Emory Vaccine Center, Emory University
PRINCIPAL_INVESTIGATORGuillaume Poliquin, MD, FRCPC
Health Canada, 539 John Buhler Research Center, Winnipeg, Canada
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 245 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 240 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 25 Participants |
| Race (NIH/OMB) Black or African American | 21 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants |
| Race (NIH/OMB) White | 195 Participants |
| Region of Enrollment Canada | 40 participants |
| Region of Enrollment United States | 208 participants |
| Sex: Female, Male Female | 119 Participants |
| Sex: Female, Male Male | 129 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 248 | 0 / 57 | 0 / 57 |
| other Total, other adverse events | 89 / 248 | 35 / 57 | 5 / 57 |
| serious Total, serious adverse events | 11 / 248 | 1 / 57 | 3 / 57 |
Outcome results
None listed